Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2007

Cegedim to Pick Up Dendrite for $751M

  • Cegedim, French maker of software for the life sciences industry, will spend $751 million for Dendrite International to expand the reach of its services into the U.S. and Asia-Pacific region.

    The offering of $16 per share represents a 25% premium over Dendrite’s closing price the day before the proposal. Dendrite opened trading at $15.61.

    Cegedim expects the combined company to have estimated pro forma annual revenues of $1.1 billion and operate in more than 75 countries across Europe, the Americas, and Asia-Pacific.

    "We are very excited to join forces with Dendrite's talented team to create a truly global business with increased international reach, a broader scope of product offerings, and the strength to invest in the development of innovative technologies," remarks Jean-Claude Labrune, founder, chairman, and CEO of Cegedim.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »